Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITY-NHL: Ublituximab + Umbralisib +/- Bendamustine in NHL
NCT02793583Phase 3Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- May 2016
- Primary completion
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of ublituximab, umbralisib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), sponsored by TG Therapeutics, Inc.. Started May 2016; status: terminated.
02
Drugs
ublituximabumbralisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02793583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02793583.